• Home
  • About Us
    • Company Overview
    • Management
    • Board of Directors
    • Advisors
    • Partnerships
    • Careers
  • Research & Development
    • Pipeline
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Data
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
    • Governance
      • Documents & Charters
      • Committee Composition
    • Shareholder Resources
      • Email Alerts
      • FAQs
  • Contact

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025 | Press Releases

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Jun 25, 2025 | Press Releases

CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025 | Press Releases

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025 | Press Releases

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple...

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | Press Releases

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...
« Older Entries

Recent Posts

  • Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
  • Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
  • Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
  • Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
  • Reviva to Participate in Upcoming Investor Conferences in May 2025

Recent Comments

No comments to show.

CONTACT

Reviva Pharmaceuticals Holdings, Inc.
10080 N Wolfe Road, Suite SW3-200
Cupertino, CA 95014

Phone: +1.408.501.8881
Email: [email protected]

  • Follow
  • Follow
Sign Up for Email Alerts

SITE LINKS

  • Home
  • Investors
  • Newsroom
  • Privacy Policy
  • Contact
  • Sitemap

Our COMPANY

  • About us
  • Management
  • Board of Directors
  • Advisors
  • Partnerships
  • Careers

RESEARCH & DEVELOPMENT

  • Pipeline
  • Clinical Trials
  • Publications
Reviva Pharmaceuticals Holdings, Inc. ©2025.   All Rights Reserved.
We value your privacy. We use cookies and other technologies to keep the site reliable and secure, measure site performance, tailor your experience, and deliver up to date stock data and financial information. By using our site, you agree to our use of cookies as described in our Privacy Policy.